Lifecore Biomedical, Inc. De (LFCR) Cash from Restructuring (2020 - 2023)

Lifecore Biomedical's Cash from Restructuring history runs 4 years deep, the most recent figure standing at -$3.5 million for Q2 2023.

• In Q2 2023, Cash from Restructuring rose 39.13% year-over-year to -$3.5 million; the TTM figure through May 2023 stood at $640000.0 (changed N/A YoY), while the FY2024 annual figure was $1.4 million, up 119.06% from the prior year.
• Cash from Restructuring was -$3.5 million for Q2 2023 at Lifecore Biomedical, down from $2.6 million in the prior quarter.
• In the past five years, Cash from Restructuring ranged from a high of $6.7 million in Q3 2020 to a low of -$5.8 million in Q2 2022.
• Historically, Cash from Restructuring has averaged $1.3 million across 4 years, with a median of $1.1 million in 2020.
• Biggest YoY gain for Cash from Restructuring was 1238.04% in 2022; the steepest drop was 206.12% in 2022.
• A 4-year view of Cash from Restructuring shows it stood at $1.1 million in 2020, then slumped by 42.95% to $627000.0 in 2021, then retreated by 10.21% to $563000.0 in 2022, then tumbled by 728.06% to -$3.5 million in 2023.
• The last three Cash from Restructuring figures came in at -$3.5 million (Q2 2023), $2.6 million (Q1 2023), and $563000.0 (Q4 2022), per Business Quant data.